Advertisement

Multiple endokrine Neoplasien

  • Michael M. Ritter
  • Wolfgang Höppner
Part of the Molekulare Medizin book series (MOLMED)

Zusammenfassung

Multiple endokrine Neoplasien (MEN) stellen vererbte, neoplastische Veränderungen dar, die auf bekannte, definieriegenetischeVeränderungen zurückzuführen sind. Häufig sind mehrere endokrine Organe desselben Patienten von der MEN betroffen, aber auch Manifestationen an nur einem einzigen Organ sind möglich. Ältere Bezeichnungen wie „pluriglanduläre Syndrome“ oder „multiple endokrine Adenomatöse“ haben sich nicht durchgesetzt und sollten aufgrund der nachweisbaren hyperplastischen und neoplastischen Veränderungen zugunsten des Begriffs „MEN“ verlassen werden.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Agarwal SK, Kester MB, Debelenko LV et al. (1997) Germline mutations of the MEN 1 gene in familial multiple endocrine neoplasia type 1 and related states. Hum Mol Genet 6:1169–1175PubMedCrossRefGoogle Scholar
  2. Agarwal SK, Guru SC, Heppner C et al. (1999 a) Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell 96:143–152PubMedCrossRefGoogle Scholar
  3. Agarwal SK, Heppner C, Collins R et al. (1999b) Menin function: a role in API-mediated gene regulation (abstract). 7th International Workshop on Multiple Endocrine Neoplasia, Gubbio, Italy, pp 19–24Google Scholar
  4. Akerstrom G, fohansson H, Grama D (1991) Surgical treatment of endocrine pancreatic lesions in MEN-1. Acta Oncol 30:541–545PubMedCrossRefGoogle Scholar
  5. Bassett JHD, Forbes SA, Pannett AAJ et al. (1998) Characterization of mutations in patients with multiple endocrine neoplasia type 1. Am J Hum Genet 62:232–244PubMedCrossRefGoogle Scholar
  6. Berndt I, Reuter M, Sailer B et al. (1998) A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2 A. J Clin Endocrinol Metab 83:770–774PubMedCrossRefGoogle Scholar
  7. Brauch H, Hoeppner W, Jähnig H et al. (1997) Sporadic pheochromocytornas are rarely associated with germline mutations in the vhl tumor suppressor gene or the ret protooncogene. J Clin Endocrinol Metab 82:4101–4104PubMedCrossRefGoogle Scholar
  8. Buj-Bello A, Adu J, Pinon LG et al. (1997) Neurlurin responsiveness requires a GP1-linked receptor and the Ret receptor tyrosine kinase. Nature 387:721–724PubMedCrossRefGoogle Scholar
  9. Calender A, Zhang CX, Giraud S, Gaudray P in the frame of GENEM (1999) MENI: phenotype/genotype correlations in MEN 1 (abstract). 7th International Workshop on Multiple Endocrine Neoplasia, Gubbio, Italy, pp 35–39Google Scholar
  10. Carty SE, Helm AK, Amico JA et al. (1998) The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1. Surgery 124:1106–1114PubMedCrossRefGoogle Scholar
  11. Chandrasekharappa SC, Guru SC, Manickam P et al. (1997) Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276:404–407PubMedCrossRefGoogle Scholar
  12. Conte-Devolx B, Nguyen L, Niccoli-Sire P (1999) Pheochromocytoma in multiple endocrine neoplasia type 2; diagnosis and treatment (abstract). 7th International Workshop on Multiple Endocrine Neoplasia, Gubbio, Italy, pp 119–123Google Scholar
  13. Cote G, Sellin RV, Sherman SI, Schultz PN, Gagel RF (1999) Clinical management of multiple endocrine neoplasia type 2 — is there an additional clinical phenotype (abstract)? 7th International Workshop on Multiple Endocrine Neoplasia, Gubbio, Italy, pp 77–78Google Scholar
  14. Darling TN, Skarulis MC, Steinberg SM, Marx SI, Spiegel AM, Turner M (1997) Multiple facial angiofibromas and collagenomas in patients with multiple endocrine neoplasia type 1. Arch Dermatol 133:853–857PubMedCrossRefGoogle Scholar
  15. Doherty GM, Olson JA, Frisella MM, Lairmore TC, Wells SA, Norton JA (1998) Lethality of multiple endocrine neoplasia type I. World J Surg 22:581–587PubMedCrossRefGoogle Scholar
  16. Donis-Keller H, Dou S, Chi D et al. (1993) Mutations in the RET proto-onocogene are associated with MEN2A and FMTC. Hum Mol Genet 2:851–856PubMedCrossRefGoogle Scholar
  17. Donow C, Pipeleers-Marichal M, Schroder S, Stamm B, Fleitz PU, Klöppel G (1991) Surgical pathology of gastrinoma. Site, size, multicentricity, association with multiple endocrine neoplasia type 1, and malignancv. Cancer 68:1329–1334PubMedCrossRefGoogle Scholar
  18. Doppmann JL, Chang R, Fraker DL et al. (1995) Localization of insulinomas to regions of the pancreas by intraarterial stimulation with calcium. Ann Intern Med 123:269–273Google Scholar
  19. Dralle H, Damm I, Scheumann GFW et al. (1994) Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma. Jpn J Surg 24:112–121CrossRefGoogle Scholar
  20. Dralle H, Höppner W, Raue F (1996) Prophylaktische Thyreoidektomie — Konsequenzen der genetischen Diagnostik in Familien mit multipler endokriner Neoplaise Typ 2. Dtsch Arztebl 93:899–901Google Scholar
  21. Dralle H, Gimm O, Simon D et al. (1998) Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience. World J Surg 22:744–750PubMedCrossRefGoogle Scholar
  22. Eisenberg AA, Wallerstein H (1932) Pheochromocytoma of the suprarenal medulla (paraganglioma). A clinicopathological story. Arch Pathol 14:818–836Google Scholar
  23. Erdheim J (1903) Zur normalen und pathologischen Histologie der Glandula thyroidea, parathyroidea und Hypophysis. Beitr Pathol Anat 33:158–236Google Scholar
  24. Frank-Raue K, Höppner W, Frilling A et al. (1996) Mutations of the ret protoonocogene in German multiple endocrine neoplasia families: relation between genotype and phenotype.) Clin Endocrinol Metab 81:1780–1783CrossRefGoogle Scholar
  25. Guru SC, Goldsmith PK, Burns AL et al. (1998) Menin, the product of the MEN 1 gene is a nuclear protein. Proc Natl Acad Sci USA 95:1630–1634PubMedCrossRefGoogle Scholar
  26. Höppner W, Ritter MM (1997) A duplication of 12 bp in the critical cysteine rich domain of the RET proto-oncogene results in a distinct phenotype of multiple endocrine neoplasia typ 2 A. Hum Mol Genet 6:587–590PubMedCrossRefGoogle Scholar
  27. Höppner W, Dralle H, Brabant G (1997) A duplication of 9 base pairs in the critical cysteine rich domain of the RET proto-oncogene causes multiple endocrine neoplasia type 2 A. Hum Mol Genet 6:128–130CrossRefGoogle Scholar
  28. Höppner W, Ark D, Klein U (1999) KfcT gene mutations in multiple endocrine neoplasia type 2 and related syndromes (abstract). 7th International Workshop on Multiple Endocrine Neoplasia, Gubbio, Italy, pp 79–83Google Scholar
  29. Howard TJ, Passaro E Jr (1990) The current status of the surgical and medical treatment of the Zollinger-Ell is on syndrome. Surg Annu 22:93–106PubMedGoogle Scholar
  30. Ito S, Iwashita T, Asai N et al. (1997) Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2 A, familial medullary thyroid carcinoma and Hirschsprung’s disease phenotype. Cancer Res 57:2870–2872PubMedGoogle Scholar
  31. Jensen RT (1998) Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1. J Intern Med 243:477–488.PubMedCrossRefGoogle Scholar
  32. Jensen RT (1999) MEN-I carcinoids: diagnosis and therapy (abstract). 7th International Workshop on Multiple Endocrine Neoplasia, Gubbio, Italy, pp 67–72 (abstract)Google Scholar
  33. Kempter B, Ritter MM (1991) Unexpected high calcitonin concentrations after pentagastrin stimulation. Clin Chem 37:473–474PubMedGoogle Scholar
  34. Kroode HFJ ten, Grosfeld FJM, Lips CJM, Beemer FA, Brouwers-Smalbraak GJ (1997) How informational and other psychosocial problems of DNA-analysis in multiple endocrine neoplasia are solved in the Netherlands. 6th International Workshop on Multiple Endocrine Neoplasia and von Hippel-Lindau disease. Noordwijkerhout-The Netherlands, 112 (abstract)Google Scholar
  35. Lips CJM, Landsvater RM, Höppner JWM et al. (1994) Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2 A. N Engl J Med 331:828–835PubMedCrossRefGoogle Scholar
  36. Lips CJM, Jansen M, Höppener JWM et al. (1999) Genotypephenotype correlations in MEN 2; their significance for clinical management. 7th International Workshop on multiple endocrine neoplasia. Gubbio-Italy, 91–95 (abstract)Google Scholar
  37. Marx SI (1998) Multiple endocrine neoplasia type 1. In: Vogelstein B, Kinzler KW (eds) The genetic basis of human cancer. McGraw-Hill, New York, pp 489–506Google Scholar
  38. Marx S, Spiegel AM, Skarulis MC, Doppman JL, Collins FS, Liotta LA (1998) Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann Intern Med 129:484–494PubMedGoogle Scholar
  39. Metz DC, Jensen RT, Bale AE et al. (1994) Multiple endocrine neoplasia type 1: clinical features and management. In: Bilezikian JP, Marcus R, Levine MA (eds) The parathyroids: basic and clinical concepts. Raven Press, New York, pp 591–646Google Scholar
  40. Mignon M, Ruszniewski P, Podevin P et al. (1993) Current approach to the management of gastrinoma and insulinoma in adults with multiple endocrine neoplasia type I. World J Surg 17:489–497PubMedCrossRefGoogle Scholar
  41. Mulligan LM, Kwok JBJ, Healey CS et al. (1993) Germ-line mutations of the RET pro to-oncogene in multiple endocrine neoplasia type 2a (MEN 2A). Nature 363:458–469PubMedCrossRefGoogle Scholar
  42. Norton JA, Fraker DL, Alexander R et al. (1999) Surgery to cure the Zollinger-Ellisonsyndrome. N Engl J Med 341:635–644PubMedCrossRefGoogle Scholar
  43. Öberg K, Skogseid B (1998) The ultimate biochemical diagnosis of endocrine pancreatic tumours in MEN-1. I Intern Med 243:471–476Google Scholar
  44. Pack S, Turner ML, Zhuang Z et al. (1998) Cutaneous tumors in patients with multiple endocrine neoplasia type 1 show allelic deletion of the MEN 1 gene. J Invest Dermatol 11:438–440CrossRefGoogle Scholar
  45. Ponder BAI, Smith D (1996) The MEN II syndromes and the role of the ret pro to-oncogene. Adv Cancer Res 70:179–222PubMedCrossRefGoogle Scholar
  46. Ponder BA, Ponder MA, Coffey R et al. (1988) Risk estimation and screening in families of patients with medullary thyroid carcinoma. Lancet 1:397–396PubMedCrossRefGoogle Scholar
  47. Rane F (1998) German medullary thyroid carcinoma/multiple endocrine neoplasia registry. German MTC/MEN Study Group. Langenbecks Arch Surg 383:334–336CrossRefGoogle Scholar
  48. Raue F (1999) Sporadic medullary thyroid carcinoma: diagnosis and treatment (abstract). 7th Internalional Workshop on Multiple Endocrine Neoplasia, Gubbio, Italy, pp 107–111Google Scholar
  49. Raue F, Frank-Raue K, Höppner W, Frilling A (1994a) Multiple Endokrine Neoplasie Typ 2. Dtsch Arztebl 91:3440–3444Google Scholar
  50. Raue F, Frank-Raue K, Grauer A (1994b) Multiple endocrine neoplasia type 2, clinical features and screening. Endocrinol Metab Clin North Am 23:137–156PubMedGoogle Scholar
  51. Ritter MM, Höppner W (1999) Multiple endokrine Neoplasien (MEN). Internist 40:486–492PubMedCrossRefGoogle Scholar
  52. Ritter MM, Frilling A, Crossey A et al. (1996) Isolated familial pheochromocytoma as a variant of von Hippel-Lindau disease. J Clin Endocrinol Metab 81:1035–1037PubMedCrossRefGoogle Scholar
  53. Rossier PH, Dreßler M (1939) Familiäre Erkrankung innersekretorischer Drüsen, kombiniert mit Ulkuserkrankung. Schweiz Med Wochenschr 69:985–990Google Scholar
  54. Santoro M, Carlomagno F, Romano A et al. (1995) Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN 2B. Science 267:381–383PubMedCrossRefGoogle Scholar
  55. Shepherd JJ (1991) The natural history of multiple endocrine neoplasia type 1. Highly uncommon or highly unrecognized? Arch Surg 126:935–952PubMedCrossRefGoogle Scholar
  56. Shepherd JJ, Challis DR, Davies PF, McArdle JP, Teh BT, Wilkinson S (1993) Multiple endocrine neoplasm, type 1. Gastrinomas, pancreatic neoplasms, micro carcinoids, the Zollinger-Ellison syndrome, lymph nodes, and hepatic metastases. Arch Surg 128:1133–1142PubMedCrossRefGoogle Scholar
  57. Sipple JH (1961) The association of pheochromocytoma with carcinoma of the thyroid gland. Am J Med 31:163–166CrossRefGoogle Scholar
  58. Skogseid B, Oberg K, Benson L et al. (1987) A standardized meal stimulation test of the endocrine pancreas for early detection of pancreatic endocrine tumors in multiple endocrine neoplasia type 1 syndrome: five years experience. J Clin Endocrinol Metab 64:1233–1240PubMedCrossRefGoogle Scholar
  59. Spada A, Corbetta S, Peracchi M (1999) MEN 1 pituitary tumors (abstract). 7th International Workshop on Multiple Endocrine Neoplasia, Gubbio, Italy, pp 63–65Google Scholar
  60. Stadil F, Stage JG (1979) The Zollinger-Ellison syndrome. Clin Endocrinol Metab 8:433–446PubMedCrossRefGoogle Scholar
  61. Steiner AL, Goodman AD, Powers SR (1968) Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyreoidism and cushing’s disease: multiple endocrine neoplasia, type 2. Medicine (Baltimore) 47:371–409CrossRefGoogle Scholar
  62. Tamburrano G, Paoloni A, Baldelli R (1999) MEN-I and insulinoma: diagnosis and therapy (abstract). 7th International Workshop on Multiple Endocrine Neoplasìa, Gubbio, Italy, pp 55–62Google Scholar
  63. Thakker RV (1998) Multiple endocrine neoplasia — syndromes of the twentieth century. J Clin Endocrinol Metab 83:2617–2620PubMedCrossRefGoogle Scholar
  64. Thompson NW (1998) Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic-duodenal disease. Results in the treatment of 40 patients with the Zollinger-Ellis on syndrome, hypoglycemia or both. J Intern Med 243:495–500PubMedCrossRefGoogle Scholar
  65. Thompson NW, Lloyd RB, Nishiyama RH et al. (1984) MEN I pancreas; a histological and immunohistological study. World J Surg 8:561–574PubMedCrossRefGoogle Scholar
  66. Thompson NW, Fasieka J, Fukuuchi A (1993) Duodenal gastrinomas, duodenotomy, and duodenal exploration in the surgical management of Zollinger-Ellison syndrome. World J Surg 17:455–462PubMedCrossRefGoogle Scholar
  67. Trump D, Farren B, Wooding C et al. (1996) Clinical studies of multiple endocrine neoplasia type 1 (MEN 1). QJM 89:653–669PubMedCrossRefGoogle Scholar
  68. Trupp M, Arenas E, Fainzilber M et al. (1996) Functional receptor for GDNF encoded by the c-ret pro to-oncogene. Nature 381:785–789PubMedCrossRefGoogle Scholar
  69. Underdahl LO, Woolner LB, Black BM (1953) Multiple endocrine adenomas: report of eight cases in which the parathyroids, pituitary and pancreatic islets were involved. J Clin Endocrinol Metab 13:20–27PubMedCrossRefGoogle Scholar
  70. Weber HC, Venzon DJ, Lin JT et al. (1995) Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 108:1637–1649PubMedCrossRefGoogle Scholar
  71. Wells SA Jr, Baylin SB, Linehan WM, Farrell RE, Cox EB, Cooper CW (1978) Provocative agents and the diagnosis of medullary carcinoma of the thyroid gland. Ann Surg 188:139–141PubMedCrossRefGoogle Scholar
  72. Wermer P (1954) Genetic aspects of adenomatosis of endocrine glands. Am J Med 16:363–372PubMedCrossRefGoogle Scholar
  73. Wolfe HJ, Delellis RA (1981) Familial medullary thyroid carcinoma and C cell hyperplasia. Clin Endocrinol Metab 10:351–365PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2001

Authors and Affiliations

  • Michael M. Ritter
    • 1
  • Wolfgang Höppner
    • 2
  1. 1.Medizinische KlinikVon-Bodelschwingh-KrankenhausIbbenbüren
  2. 2.Universität HamburgInstitut für Hormon- und FortpflanzungsforschungHamburg

Personalised recommendations